Ionis Pharmaceuticals, Inc. (IONS)
NASDAQ: IONS · Real-Time Price · USD
56.92
+1.50 (2.71%)
Aug 12, 2026, 12:13 PM EDT - Market open
Ionis Pharmaceuticals Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 350.07 | 372.26 | 242.08 | 399.27 | 276.47 | 869.19 |
Short-Term Investments | 1,705 | 2,305 | 2,056 | 1,932 | 1,710 | 1,246 |
Cash & Short-Term Investments | 2,055 | 2,677 | 2,298 | 2,331 | 1,987 | 2,115 |
Cash Growth | -10.28% | 16.53% | -1.44% | 17.33% | -6.06% | 11.76% |
Accounts Receivable | 58.85 | 66.06 | 92.19 | 97.78 | 25.54 | 61.9 |
Inventory | 50.83 | 10.05 | 12.51 | 7.44 | 22.03 | 24.81 |
Other Current Assets | 327.01 | 237.09 | 217.93 | 205.43 | 168.25 | 143.37 |
Total Current Assets | 2,491 | 2,991 | 2,620 | 2,642 | 2,203 | 2,345 |
Net Property, Plant & Equipment | 386.69 | 361.6 | 256.11 | 242.94 | 255.84 | 196.04 |
Other Long-Term Assets | 116.54 | 171.6 | 127.28 | 105.28 | 75.34 | 70.6 |
Total Assets | 2,995 | 3,524 | 3,004 | 2,990 | 2,534 | 2,612 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 47.7 | 28.08 | 42.96 | 26.03 | 17.92 | 11.9 |
Accrued Expenses | 166.07 | 222.33 | 178.05 | 215.62 | 189.28 | 127.37 |
Current Portion of Long-Term Debt | - | 431.95 | - | 44.33 | - | - |
Unearned Revenue | 73.84 | 73.76 | 78.99 | 151.13 | 90.58 | 97.71 |
Other Current Liabilities | 28.03 | 25.45 | 9.31 | 10.98 | 13.78 | 3.56 |
Total Current Liabilities | 315.64 | 781.57 | 309.32 | 448.09 | 311.56 | 240.55 |
Long-Term Debt | 1,351 | 1,347 | 1,245 | 1,230 | 1,183 | 1,228 |
Long-Term Leases | 262.48 | 262.38 | 161.81 | 170.88 | 178.94 | 19.43 |
Other Long-Term Liabilities | 625.6 | 643.35 | 698.72 | 754.92 | 287.77 | 351.88 |
Total Long-Term Liabilities | 2,239 | 2,253 | 2,106 | 2,155 | 1,649 | 1,599 |
Total Liabilities | 2,555 | 3,035 | 2,415 | 2,603 | 1,961 | 1,840 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.17 | 0.16 | 0.16 | 0 | 0 | 0.14 |
Additional Paid-in Capital | 3,312 | 3,145 | 2,869 | 2,215 | 2,060 | 1,964 |
Accumulated Other Comprehensive Income | -33.9 | -25.28 | -30.81 | -32.65 | -57.48 | -32.67 |
Retained Earnings | -2,838 | -2,631 | -2,250 | -1,796 | -1,430 | -1,160 |
Total Common Shareholders' Equity | 439.74 | 489.09 | 588.35 | 386.54 | 572.75 | 771.74 |
Shareholders' Equity | 439.74 | 489.09 | 588.35 | 386.69 | 572.89 | 771.74 |
Total Liabilities & Equity | 2,995 | 3,524 | 3,004 | 2,990 | 2,534 | 2,612 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,614 | 2,042 | 1,407 | 1,445 | 1,362 | 1,248 |
Net Cash (Debt) | 441.06 | 635.66 | 890.37 | 886.49 | 625.21 | 867.45 |
Net Cash Growth | -49.30% | -28.61% | 0.44% | 41.79% | -27.93% | -8.95% |
Net Cash Per Share | 2.71 | 3.97 | 5.96 | 6.19 | 4.41 | 6.15 |
Book Value | 439.74 | 489.09 | 588.35 | 386.54 | 572.75 | 771.74 |
Book Value Per Share | 2.70 | 3.06 | 3.94 | 2.70 | 4.04 | 5.47 |
Tangible Book Value | 439.74 | 489.09 | 588.35 | 386.54 | 572.75 | 771.74 |
Tangible Book Value Per Share | 2.70 | 3.06 | 3.94 | 2.70 | 4.04 | 5.47 |